0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover254.41%IV-5.12%PremiumDec 20, 2024Expiry Date0.54Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.6357Delta0.0778Gamma4.90Leverage Ratio-0.0789Theta0.0015Rho3.12Eff Leverage0.0071Vega
Y-mAbs Therapeutics Stock Discussion
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also...
No comment yet